HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
RPL14
ribosomal protein L14
Chromosome 3 · 3p22.1
NCBI Gene: 9045Ensembl: ENSG00000188846.14HGNC: HGNC:10305UniProt: P50914
296PubMed Papers
20Diseases
6Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
RNA bindingstructural constituent of ribosomeprotein bindingcadherin bindinginfluenzaDuchenne muscular dystrophyneurodegenerative diseasecystic fibrosis
✦AI Summary

RPL14 encodes ribosomal protein L14, a component of the large ribosomal subunit essential for protein synthesis in cells 123. The protein contains conserved structural elements including a KOW-motif and nuclear localization signal, with some species variation in polyalanine repeat regions 4. RPL14 functions as a tumor suppressor gene, with reduced expression observed in nasopharyngeal carcinoma where overexpression inhibits cell proliferation, migration, invasion, and epithelial-mesenchymal transition 5. Located at chromosome 3.3, RPL14 shows frequent loss of heterozygosity in lung cancer (75% of cell lines vs 32% in normal population) and esophageal squamous cell carcinoma (43% of tumors), suggesting early involvement in tumorigenesis 67. Genetic variants in RPL14, particularly rs2276868, are associated with nasopharyngeal carcinoma susceptibility and modulate EBV infection pathways 8. In neurological contexts, RPL14 expression is upregulated in Alzheimer's disease brain capillaries as part of enhanced ribosomal complex activity 9, and its expression changes are linked to inflammatory responses in spinal cord injury 10.

Sources cited
1
RPL14 is a component of the large ribosomal subunit responsible for protein synthesis
PMID: 12962325
2
RPL14 is part of the ribonucleoprotein complex for protein synthesis
PMID: 23636399
3
RPL14 functions in the ribosomal complex for cellular protein synthesis
PMID: 32669547
4
RPL14 protein contains KOW-motif and nuclear localization signal with species variation in polyalanine repeats
PMID: 15061815
5
RPL14 acts as tumor suppressor in nasopharyngeal carcinoma, inhibiting proliferation, migration, invasion and EMT
PMID: 34057029
6
RPL14 shows loss of heterozygosity in 75% of lung cancer cell lines vs 32% in normal population, located at 3p21.3
PMID: 9920051
7
RPL14 shows 43% loss of heterozygosity in esophageal squamous cell carcinomas, suggesting early tumorigenesis role
PMID: 16316724
8
RPL14 variant rs2276868 associated with nasopharyngeal carcinoma susceptibility and EBV infection modulation
PMID: 39744943
9
RPL14 is significantly upregulated in Alzheimer's disease brain capillaries as part of ribosomal complex enhancement
PMID: 35766008
10
RPL14 expression changes are linked to inflammatory responses in spinal cord injury
PMID: 40345018
Disease Associationsⓘ20
influenzaOpen Targets
0.46Moderate
Duchenne muscular dystrophyOpen Targets
0.46Moderate
neurodegenerative diseaseOpen Targets
0.41Moderate
cystic fibrosisOpen Targets
0.39Weak
pulmonary vascular congestionOpen Targets
0.28Weak
aniridiaOpen Targets
0.10Suggestive
Becker muscular dystrophyOpen Targets
0.10Suggestive
nasopharyngeal carcinomaOpen Targets
0.09Suggestive
non-Hodgkins lymphomaOpen Targets
0.09Suggestive
genetic disorderOpen Targets
0.09Suggestive
hepatitis B virus infectionOpen Targets
0.08Suggestive
epilepsyOpen Targets
0.08Suggestive
hepatocellular carcinomaOpen Targets
0.07Suggestive
Alport syndromeOpen Targets
0.07Suggestive
arthritisOpen Targets
0.07Suggestive
cystinosisOpen Targets
0.07Suggestive
diffuse large B-cell lymphomaOpen Targets
0.07Suggestive
Dravet syndromeOpen Targets
0.07Suggestive
hemophilia AOpen Targets
0.07Suggestive
muscular dystrophyOpen Targets
0.07Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets6
ATALURENApproved
80S Ribosome modulator
Duchenne muscular dystrophy
CITATUZUMAB BOGATOXPhase I
Epithelial cell adhesion molecule binding agent
ELX-02Phase II
80S Ribosome modulator
cystic fibrosis
MT-3724Phase II
80S Ribosome inhibitor
diffuse large B-cell lymphoma
TELIMOMAB ARITOXPhase II
T-cell surface glycoprotein CD5 binding agent
hepatitis B virus infection
ZOLIMOMAB ARITOXPhase II
T-cell surface glycoprotein CD5 binding agent
arthritis
Related Genes
RPL35AProtein interaction100%BTF3Protein interaction100%EEF1A1Protein interaction100%EEF1B2Protein interaction100%EEF2Protein interaction100%EIF5AProtein interaction100%
Tissue Expression6 tissues
Ovary
100%
Lung
50%
Bone Marrow
44%
Liver
40%
Brain
35%
Heart
33%
Gene Interaction Network
Click a node to explore
RPL14RPL35ABTF3EEF1A1EEF1B2EEF2EIF5A
PROTEIN STRUCTURE
Preparing viewer…
PDB8A3D · 1.67 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.36Moderately Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.16 [0.08–0.36]
RankingsWhere RPL14 stands among ~20K protein-coding genes
  • #1,189of 20,598
    Most Researched296 · top 10%
  • #794of 1,025
    FDA-Approved Drug Targets1
  • #1,601of 17,882
    Most Constrained (LOEUF)0.36 · top 10%
Genes detectedRPL14
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma.
PMID: 34057029
Bioengineered · 2021
1.00
2
Whole-exome sequencing association study reveals genetic effects on tumor microenvironment components in nasopharyngeal carcinoma.
PMID: 39744943
J Clin Invest · 2025
0.90
3
Identification and comparative analysis of the RpL14 gene from Takifugu rubripes.
PMID: 15061815
Hereditas · 2003
0.80
4
Upregulation of ribosome complexes at the blood-brain barrier in Alzheimer's disease patients.
PMID: 35766008
J Cereb Blood Flow Metab · 2022
0.70
5
Coronary artery disease risk factors affected by RNA modification-related genetic variants.
PMID: 36204584
Front Cardiovasc Med · 2022
0.68